Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049010 · ClinicalTrials.gov registry record · NA
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
A NA study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- NA
- Development phase
- 314
- Enrollment target
NCT00049010: Completed NA study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00049010 is a NA study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 314 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049010, a NA study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer. PURPOSE: This clinical trial is studying tumor tissue and lymph node samples to see how well they work in predicting the development of metastatic cancer in patients with stage I or stage II melanoma.
Interventions
- OTHER immunohistochemistry staining method
- GENETIC cytogenetic analysis
- GENETIC fluorescence in situ hybridization
- GENETIC comparative genomic hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2002-09 |
| Est. Completion | 2009-10 |
| Phase | NA |
What the finished NCT00049010 record still lists
NCT00049010 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 4 interventions - of which immunohistochemistry staining method is the first listed.
NCT00049010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049010 about?
NCT00049010 is a clinical study titled "Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma". RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer. PURPOSE: This clinical trial is studying tumor tissue and lymph node samples to see how well they w...
What is the current status of trial NCT00049010?
This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2002-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00049010?
The interventions under investigation include: immunohistochemistry staining method (OTHER), cytogenetic analysis (GENETIC), fluorescence in situ hybridization (GENETIC), comparative genomic hybridization (GENETIC).
Who is sponsoring clinical trial NCT00049010?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00049010's enrollment target sits among peer trials
314 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia